(CTVA) Corteva - Ratings and Ratios
Seeds, Traits, Herbicides, Insecticides, Digital
CTVA EPS (Earnings per Share)
CTVA Revenue
Description: CTVA Corteva September 29, 2025
Corteva Inc. (NYSE: CTVA) is a pure-play agriculture input company that operates through two complementary segments – Seed and Crop Protection. The Seed segment focuses on advanced germplasm and trait technologies that boost yield, improve resistance to weather, disease, insects and herbicides, and add food-quality attributes, while also delivering digital decision-support tools to help growers optimize inputs and profitability.
The Crop Protection segment supplies a portfolio of herbicides, insecticides, nitrogen stabilizers, and pasture-range herbicides, plus seed-applied solutions that protect crops from weeds, pests, and diseases and enhance root-zone health. Both segments serve a global customer base spanning North America, Latin America, Europe, Asia-Pacific, the Middle East and Africa.
Key quantitative highlights (FY 2023) include total revenue of roughly $6.2 billion, with the Seed business contributing about 55 % of sales and Crop Protection the remaining 45 %. R&D expenditures were approximately $1.1 billion, reflecting a strong pipeline of CRISPR-based traits and next-generation chemistries. Corteva’s seed market share in U.S. corn remains near 30 %, and its herbicide portfolio benefits from a growing demand for nitrogen-stabilizing products as growers seek to improve nitrogen use efficiency under tighter environmental regulations.
Primary economic drivers for Corteva are global commodity price cycles, which influence growers’ willingness to invest in higher-cost seed and protection products, and the accelerating shift toward sustainable agriculture – a trend that fuels adoption of digital agronomy tools and low-environment-impact chemistries. Regulatory scrutiny of certain herbicide classes also creates both risk and opportunity, as the company pivots toward newer modes of action and biologically based solutions.
For a deeper quantitative assessment, you may find the ValueRay platforms granular financial models and scenario analyses useful.
CTVA Stock Overview
| Market Cap in USD | 41,724m |
| Sub-Industry | Fertilizers & Agricultural Chemicals |
| IPO / Inception | 2019-05-24 |
CTVA Stock Ratings
| Growth Rating | 32.4% |
| Fundamental | 64.8% |
| Dividend Rating | 57.0% |
| Return 12m vs S&P 500 | -14.0% |
| Analyst Rating | 4.29 of 5 |
CTVA Dividends
| Dividend Yield 12m | 1.10% |
| Yield on Cost 5y | 2.17% |
| Annual Growth 5y | 6.14% |
| Payout Consistency | 100.0% |
| Payout Ratio | 21.4% |
CTVA Growth Ratios
| Growth Correlation 3m | -83.2% |
| Growth Correlation 12m | 65.5% |
| Growth Correlation 5y | 72.5% |
| CAGR 5y | -1.31% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.04 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.10 |
| Sharpe Ratio 12m | 0.11 |
| Alpha | -12.78 |
| Beta | 0.765 |
| Volatility | 25.53% |
| Current Volume | 5173.5k |
| Average Volume 20d | 4379.7k |
| Stop Loss | 60.6 (-3%) |
| Signal | 0.79 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (1.40b TTM) > 0 and > 6% of Revenue (6% = 1.03b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 2.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 37.77% (prev 37.90%; Δ -0.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 3.14b > Net Income 1.40b (YES >=105%, WARN >=100%) |
| Net Debt (1.56b) to EBITDA (3.46b) ratio: 0.45 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (683.1m) change vs 12m ago -2.15% (target <= -2.0% for YES) |
| Gross Margin 45.65% (prev 43.91%; Δ 1.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.28% (prev 40.76%; Δ 0.52pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.55 (EBITDA TTM 3.46b / Interest Expense TTM 214.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.43
| (A) 0.16 = (Total Current Assets 16.00b - Total Current Liabilities 9.52b) / Total Assets 41.76b |
| (B) 0.04 = Retained Earnings (Balance) 1.53b / Total Assets 41.76b |
| (C) 0.05 = EBIT TTM 2.26b / Avg Total Assets 41.61b |
| (D) -0.07 = Book Value of Equity -1.10b / Total Liabilities 15.61b |
| Total Rating: 1.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.84
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 6.00% = 3.00 |
| 3. FCF Margin 15.10% = 3.78 |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda 0.45 = 2.34 |
| 6. ROIC - WACC (= -2.19)% = -2.74 |
| 7. RoE 5.68% = 0.47 |
| 8. Rev. Trend 26.56% = 1.99 |
| 9. EPS Trend 0.01% = 0.00 |
What is the price of CTVA shares?
Over the past week, the price has changed by -1.51%, over one month by -2.80%, over three months by -12.89% and over the past year by +3.16%.
Is Corteva a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CTVA is around 52.52 USD . This means that CTVA is currently overvalued and has a potential downside of -15.97%.
Is CTVA a buy, sell or hold?
- Strong Buy: 13
- Buy: 5
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CTVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.9 | 24.6% |
| Analysts Target Price | 77.9 | 24.6% |
| ValueRay Target Price | 58.4 | -6.5% |
CTVA Fundamental Data Overview November 04, 2025
P/E Trailing = 28.3134
P/E Forward = 17.6367
P/S = 2.4291
P/B = 1.6641
P/EG = 0.8479
Beta = 0.765
Revenue TTM = 17.18b USD
EBIT TTM = 2.26b USD
EBITDA TTM = 3.46b USD
Long Term Debt = 1.69b USD (from longTermDebt, last quarter)
Short Term Debt = 1.94b USD (from shortTermDebt, last quarter)
Debt = 3.63b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.56b USD (from netDebt column, last quarter)
Enterprise Value = 43.21b USD (41.72b + Debt 3.63b - CCE 2.14b)
Interest Coverage Ratio = 10.55 (Ebit TTM 2.26b / Interest Expense TTM 214.0m)
FCF Yield = 6.00% (FCF TTM 2.59b / Enterprise Value 43.21b)
FCF Margin = 15.10% (FCF TTM 2.59b / Revenue TTM 17.18b)
Net Margin = 8.16% (Net Income TTM 1.40b / Revenue TTM 17.18b)
Gross Margin = 45.65% ((Revenue TTM 17.18b - Cost of Revenue TTM 9.34b) / Revenue TTM)
Gross Margin QoQ = 54.58% (prev 46.98%)
Tobins Q-Ratio = 1.03 (Enterprise Value 43.21b / Total Assets 41.76b)
Interest Expense / Debt = 1.43% (Interest Expense 52.0m / Debt 3.63b)
Taxrate = 23.39% (422.0m / 1.80b)
NOPAT = 1.73b (EBIT 2.26b * (1 - 23.39%))
Current Ratio = 1.68 (Total Current Assets 16.00b / Total Current Liabilities 9.52b)
Debt / Equity = 0.14 (Debt 3.63b / totalStockholderEquity, last quarter 25.91b)
Debt / EBITDA = 0.45 (Net Debt 1.56b / EBITDA 3.46b)
Debt / FCF = 0.60 (Net Debt 1.56b / FCF TTM 2.59b)
Total Stockholder Equity = 24.68b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.35% (Net Income 1.40b / Total Assets 41.76b)
RoE = 5.68% (Net Income TTM 1.40b / Total Stockholder Equity 24.68b)
RoCE = 8.56% (EBIT 2.26b / Capital Employed (Equity 24.68b + L.T.Debt 1.69b))
RoIC = 6.02% (NOPAT 1.73b / Invested Capital 28.71b)
WACC = 8.21% (E(41.72b)/V(45.35b) * Re(8.83%) + D(3.63b)/V(45.35b) * Rd(1.43%) * (1-Tc(0.23)))
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.50%
[DCF Debug] Terminal Value 66.98% ; FCFE base≈2.16b ; Y1≈1.42b ; Y5≈649.1m
Fair Price DCF = 16.52 (DCF Value 11.22b / Shares Outstanding 679.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 0.01 | EPS CAGR: -6.13% | SUE: 2.04 | # QB: 3
Revenue Correlation: 26.56 | Revenue CAGR: 35.90% | SUE: 0.80 | # QB: 0
Additional Sources for CTVA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle